ANEB
Anebulo Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
+75.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -4.5%
- EBIT
- -13.7%
- EPS
- +33.2%
- Free cash flow
- +12.1%
- Operating cash flow
- +12.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -85.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- +2.3%
- EBIT
- -11.0%
- Net income
- -3.4%
- EPS
- +21.9%
- Free cash flow
- +21.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025